Hemostemix Presents at Puerto Rico Investor Summits: Showcasing Global Scale-Up Strategy and Economic Impact
Hemostemix (TSXV: HEM) (OTC: HMTXF) announces its participation in two Puerto Rico Investor Summits in January 2025. The company will showcase its ACP-01 therapy and global scale-up strategy at the Sequire Investor Summit and CytoImmune-hosted Event.
Key highlights include the company's Automated Cell Therapy System (ACTS), which can scale from $12 million in annual revenue to $144 million monthly. Each 10' x 10' clean room produces 2,880 ACP-01 therapies annually. The therapy demonstrates a 93.5% success rate in saving limbs from amputation for chronic limb-threatening ischemia patients, reducing the five-year mortality rate from 60% to near zero.
Through partnership with CytoImmune and leveraging Puerto Rico's ACT 60 program, Hemostemix aims to achieve 50% cost reimbursement for research conducted in Puerto Rico. The company projects an 80% reduction in healthcare costs per patient through ACP-01's healing capabilities.
Hemostemix (TSXV: HEM) (OTC: HMTXF) annuncia la sua partecipazione a due Summit per Investitori a Porto Rico nel gennaio 2025. L'azienda presenterà la sua terapia ACP-01 e la strategia di scalabilità globale al Sequire Investor Summit e all'evento ospitato da CytoImmune.
I punti salienti includono il Sistema di Terapia Cellulare Automatizzato (ACTS) dell'azienda, che può scalare da 12 milioni di dollari di ricavi annuali a 144 milioni di dollari mensili. Ogni stanza pulita di 10' x 10' produce annualmente 2.880 terapie ACP-01. La terapia dimostra un tasso di successo del 93,5% nel salvare gli arti dall'amputazione per pazienti affetti da ischemia cronica minacciosa per gli arti, riducendo il tasso di mortalità quinquennale dal 60% a quasi zero.
Attraverso una partnership con CytoImmune e sfruttando il programma ACT 60 di Porto Rico, Hemostemix mira a ottenere un rimborso del 50% dei costi per la ricerca condotta a Porto Rico. L'azienda prevede una riduzione dell'80% dei costi sanitari per paziente grazie alle capacità di guarigione dell'ACP-01.
Hemostemix (TSXV: HEM) (OTC: HMTXF) anuncia su participación en dos Cumbres de Inversores en Puerto Rico en enero de 2025. La compañía exhibirá su terapia ACP-01 y estrategia de escalado global en la Cumbre de Inversores de Sequire y el evento patrocinado por CytoImmune.
Los aspectos destacados incluyen el Sistema Automatizado de Terapia Celular (ACTS) de la compañía, que puede escalar de 12 millones de dólares en ingresos anuales a 144 millones de dólares mensuales. Cada sala limpia de 10' x 10' produce anualmente 2,880 terapias ACP-01. La terapia muestra una tasa de éxito del 93.5% en salvar extremidades de la amputación para pacientes con isquemia crónica amenazante para las extremidades, reduciendo la tasa de mortalidad a cinco años del 60% a casi cero.
A través de una asociación con CytoImmune y aprovechando el programa ACT 60 de Puerto Rico, Hemostemix busca lograr un reembolso del 50% de los costos por la investigación realizada en Puerto Rico. La compañía proyecta una reducción del 80% en los costos de atención médica por paciente gracias a las capacidades curativas de ACP-01.
Hemostemix (TSXV: HEM) (OTC: HMTXF)는 2025년 1월 푸에르토리코에서 열리는 두 개의 투자자 서밋에 참가할 것이라고 발표했습니다. 회사는 Sequire 투자자 서밋 및 CytoImmune 주최 행사에서 ACP-01 치료법과 글로벌 확장 전략을 선보일 예정입니다.
주요 하이라이트에는 회사의 자동화 세포 치료 시스템 (ACTS)이 포함되어 있으며, 연간 수익이 1,200만 달러에서 월 1억 4,400만 달러로 확장될 수 있습니다. 각 10' x 10' 클린룸은 연간 2,880개의 ACP-01 치료법을 생산합니다. 이 치료법은 만성 사지 위협 허혈 환자의 사지를 절단으로부터 구하는 성공률이 93.5%이며, 5년 사망률을 60%에서 거의 0으로 줄입니다.
CytoImmune와의 파트너십과 푸에르토리코의 ACT 60 프로그램을 활용하여 Hemostemix는 푸에르토리코에서 진행된 연구에 대해 50% 비용 환급을 달성하는 것을 목표로 하고 있습니다. 회사는 ACP-01의 치유 능력 덕분에 환자당 의료 비용을 80% 줄일 것으로 예상하고 있습니다.
Hemostemix (TSXV: HEM) (OTC: HMTXF) annonce sa participation à deux Sommets d'Investisseurs à Porto Rico en janvier 2025. L'entreprise présentera sa thérapie ACP-01 et sa stratégie de montée en échelle mondiale lors du Sequire Investor Summit et de l'événement organisé par CytoImmune.
Les points forts incluent le Système de Thérapie Cellulaire Automatisé (ACTS) de l'entreprise, qui peut passer de 12 millions de dollars de revenus annuels à 144 millions de dollars mensuels. Chaque salle propre de 10' x 10' produit 2 880 thérapies ACP-01 par an. La thérapie montre un taux de réussite de 93,5 % dans la préservation des membres des patients souffrant d'ischémie chronique menaçante pour les membres, réduisant le taux de mortalité à cinq ans de 60 % à presque zéro.
Grâce à un partenariat avec CytoImmune et en tirant parti du programme ACT 60 de Porto Rico, Hemostemix vise à obtenir un remboursement de 50 % des coûts pour la recherche effectuée à Porto Rico. L'entreprise prévoit une réduction de 80 % des coûts de santé par patient grâce aux capacités de guérison de l'ACP-01.
Hemostemix (TSXV: HEM) (OTC: HMTXF) kündigt seine Teilnahme an zwei Investoren-Gipfeln in Puerto Rico im Januar 2025 an. Das Unternehmen wird seine ACP-01-Therapie und die globale Skalierungsstrategie beim Sequire Investor Summit und der von CytoImmune ausgerichteten Veranstaltung präsentieren.
Zu den wichtigsten Highlights gehört das Automatisierte Zelltherapiesystem (ACTS) des Unternehmens, das von 12 Millionen Dollar Jahresumsatz auf 144 Millionen Dollar monatlich skalierbar ist. Jeder 10' x 10' Reinraum produziert jährlich 2.880 ACP-01-Therapien. Die Therapie zeigt eine Erfolgsquote von 93,5 % bei der Rettung von Gliedmaßen vor Amputation bei Patienten mit chronischer, gliedmaßenbedrohender Ischämie und senkt die Fünf-Jahres-Sterblichkeitsrate von 60 % auf nahezu null.
Durch die Partnerschaft mit CytoImmune und die Nutzung des ACT 60-Programms von Puerto Rico strebt Hemostemix eine Kostenerstattung von 50 % für Forschungsaktivitäten in Puerto Rico an. Das Unternehmen prognostiziert eine Reduzierung der Gesundheitskosten pro Patient um 80 % durch die Heilungskapazitäten von ACP-01.
- ACTS manufacturing system can scale from $12M annual to $144M monthly revenue
- 93.5% success rate in saving limbs from amputation
- 80% projected reduction in healthcare costs per patient
- 50% research cost reimbursement through Puerto Rico's ACT 60 program
- Each clean room produces 2,880 ACP-01 therapies annually
- Requires additional clinical trials to generate cash flow
- Still pending Phase III clinical trial completion
Calgary, Alberta--(Newsfile Corp. - January 20, 2025) - Hemostemix Inc. (TSXV: HEM) (OTC: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is proud to announce its participation in two highly anticipated Puerto Rico Investor Summits:
Sequire Investor Summit: January 22-23 at the Condado Vanderbilt Hotel.
CytoImmune-hosted Event: January 24 at CytoImmune's state-of-the-art facility in San Juan, Puerto Rico.
Thomas Smeenk, President & CEO of Hemostemix, will deliver an engaging presentation highlighting the Company's groundbreaking ACP-01 therapy, global scale-up strategy, and collaborations that are creating economic opportunities for clinicians.
Why This Matters: Key Highlights of Hemostemix's Strategy
1. Revolutionizing Therapy Production:
Scalable Manufacturing: Hemostemix's patented Automated Cell Therapy System (ACTS) can scale from
$12 million in annual revenue to$144 million monthly.Each 10' x 10' clean room produces 2,880 ACP-01 therapies annually, which enables the Company to meet global demand.
2. Life-Saving Results with ACP-01:
- Transforming Lives: ACP-01 has a
93.5% success rate in saving limbs from amputation for chronic limb-threatening ischemia (CLTI) patients, reducing the current five-year mortality rate from60% to near zero.
3. Economic and Healthcare Benefits:
- Hemostemix projects an
80% reduction in healthcare costs per patient due to ACP-01's ability to heal ulcers, relieve pain, and improve mobility.
4. Regulatory Pathway & Valuation:
Funded from cash flow, a multi-centre randomized Phase III clinical trial will further quantify ACP-01's efficacy.
To generate cash flow, the Company is announcing a number of trials, to look at how ACP-01 generates healing earlier in the disease processes of vascular dementia, peripheral arterial disease, ischemic cardiomyopathy, non ischemic dilated cardiomyoptathy, and angina.
5. Strategic Collaboration:
Hemostemix, in partnership with CytoImmune, Puerto Rico's Government, and leading healthcare professionals, is committed to advancing therapies for no-option patients with conditions such as vascular dementia, PAD, CLTI, and more.
Leveraging Puerto Rico's ACT 60 program, Hemostemix and CytoImmune plan to achieve the world's lowest R&D costs, with
50% reimbursement in cash for research conducted on the island of Puerto Rico.
"Our partnership with CytoImmune strengthens Hemostemix's ability to scale globally while delivering cost-effective, life-changing therapies to patients," stated Thomas Smeenk, President & CEO. "Puerto Rico's ACT 60 program and these investor summits allow us to demonstrate how Hemostemix is transforming regenerative medicine and healthcare economics."
About Hemostemix
Founded in 2003, Hemostemix is a clinical-stage biotechnology company recognized for its patented blood-based stem cell therapeutics platform. Hemostemix focuses on scaling angiogenic, neuronal, and cardiomyocyte cell precursors to treat no-option patients worldwide.
Learn more: www.hemostemix.com
Contact:
Thomas Smeenk, President & CEO
tsmeenk@hemostemix.com
(905) 580-4170
Stock Information: TSXV: HEM | OTC: HMTXF | FSE: 2VF0
Neither the TSX Venture Exchange nor its Regulation Service Provider (as that term is defined under the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Forward-Looking Information: This news release contains "forward-looking information" within the meaning of applicable Canadian securities legislation. All statements, other than statements of historical fact, included herein are forward-looking information. In particular, this news release contains forward-looking information in relation to sales of its lead product ACP-01, the commercialization of ACP-01 via the sale of compassionate treatments under Special Access Program. There can be no assurance that such forward-looking information will prove to be accurate. Actual results and future events could differ materially from those anticipated in such forward-looking information. This forward-looking information reflects Hemostemix's current beliefs and is based on information currently available to Hemostemix and on assumptions Hemostemix believes are reasonable. These assumptions include, but are not limited to: the underlying value of Hemostemix and its Common Shares; the successful resolution of the litigation that Hemostemix is pursuing or defending (the "Litigation"); the results of ACP-01 research, trials, studies and analyses, including the analysis being equivalent to or better than previous research, trials or studies; the receipt of all required regulatory approvals for research, trials or studies; the level of activity, market acceptance and market trends in the healthcare sector; the economy generally; consumer interest in Hemostemix's services and products; competition and Hemostemix's competitive advantages; and Hemostemix obtaining satisfactory financing to fund Hemostemix's operations including any research, trials or studies, and any Litigation. Forward-looking information is Subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of Hemostemix to be materially different from those expressed or implied by such forward-looking information. Such risks and other factors may include, but are not limited to: the ability of Hemostemix to complete clinical trials, complete a satisfactory analyses and file the results of such analyses to gain regulatory approval of a phase II or phase III clinical trial of ACP-01; potential litigation Hemostemis may face; general business, economic, competitive, political and social uncertainties; general capital market conditions and market prices for securities; delay or failure to receive board or regulatory approvals; the actual results of future operations including the actual results of future research, trials or studies; competition; changes in legislation affecting Hemostemix; the timing and availability of external financing on acceptable terms; long-term capital requirements and future developments in Hemostemix's markets and the markets in which it expects to compete; lack of qualified, skilled labour or loss of key individuals; and risks related to the COVID-19 pandemic including various recommendations, orders and measures of governmental authorities to try to limit the pandemic, including travel restrictions, border closures, non-essential business closures service disruptions, quarantines, self-isolations, shelters-in-place and social distancing, disruptions to markets, disruptions to economic activity and financings, disruptions to supply chains and sales channels, and a deterioration of general economic conditions including a possible national or global recession or depression; the potential impact that the COVID-19 pandemic may have on Hemostemix which may include a decreased demand for the services that Hemostemix offers; and a deterioration of financial markets that could limit Hemostemix's ability to obtain external financing. A description of additional risk factors that may cause actual results to differ materially from forward-looking information can be found in Hemostemix's disclosure documents on the SEDAR website at www.sedar.com. Although Hemostemix has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. Readers are cautioned that the foregoing list of factors is not exhaustive. Readers are further cautioned not to place undue reliance on forward-looking information as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Forward-looking information contained in this news release is expressly qualified by this cautionary statement. The forward-looking information contained in this news release represents the expectations of Hemostemix as of the date of this news release and, accordingly, it is Subject to change after such date. However, Hemostemix expressly disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as expressly required by applicable securities law.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/237817
FAQ
What is the revenue potential of Hemostemix's (HMTXF) ACTS manufacturing system?
What is the success rate of HMTXF's ACP-01 therapy for CLTI patients?
How many ACP-01 therapies can Hemostemix (HMTXF) produce per clean room annually?
What cost reduction does Hemostemix (HMTXF) project for healthcare with ACP-01?
What benefit does HMTXF receive from Puerto Rico's ACT 60 program?
